Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Abzena’s Chief Technical Officer offers her thought leadership.
August 4, 2023
By: Contract Pharma
What are “3 Key Trends” shaping the CDMO industry in 2023 and beyond? Abzena’s chief technical officer, Louise Duffy, shares her thoughts with Contract Pharma. The rise of antibody-drug conjugates (ADCs) Antibody-drug conjugates (ADCs) are promising therapeutics that have received considerable attention this past year, with over 50 ADCs in the pre-clinical stage and a total of 190 active clinical trials.1 Complex to produce, ADCs are composed of a highly potent payload covalently linked to an antibody. As a fast-growing therapeutic for treating cancer, ADCs can be used to specifically deliver potent cytotoxic pharmaceuticals directly to cancer cells. In addition, optimization to strengthen targeted antibody binding, increase ADC half-life, and reduce immunogenicity, have only increased their desirability as potential treatments for a range of diseases, including Alzheimer’s.2 Aided by innovation in antibody engineering and with increasingly complex ADCs being developed, the number of ADC-based therapeutics is expected to increase further. However, as their complexity increases, manufacturing becomes more challenging, leading to many CDMOs investing in more robust and efficient ADC manufacturing processes. Optimizing downstream development As stated above, manufacturing challenges increase as a product becomes more complex. This is due to production techniques and processes often requiring extensive optimization, which can lengthen the development process and lead to a longer timeline to reach the market. An increasing number of protein-drug conjugates (PDCs)—for which ADCs are an example—are currently in development. Significant investment to simplify manufacturing focus on streamlining downstream development by introducing new chromatography-based purification techniques. Some examples include using a new resin, running conventional chromatography steps in a series, or altering the chromatography mode used. Advancements in artificial intelligence and machine learning technology are also aiding timeline acceleration by helping to implement automated manufacturing processes. Increasingly potent compounds Highly potent active pharmaceutical ingredients (HPAPI) can be linked to an antibody to form a potent ADC. The ability of HPAPIs to deliver beneficial pharmacological effects at lower concentrations means a lower dose can be given to get the desired result, reducing the risk of side effects, and making HPAPI-based drugs an attractive target for treating various chronic diseases. However, many safety risks are associated with potent compounds, and strict procedures must be followed by manufacturers. This includes completing extensive risk assessments and using specialized equipment to ensure safe handling. CDMOs often have these capabilities in place and can develop and manufacture these products at speed. Potential risks are further mitigated as experts with experience in HPAPI handling are used. Therefore, many pharma companies are outsourcing the manufacture of HPAPIs, including those used for HPAPI-based ADCs, to CDMOs for efficient manufacture.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !